An additional treatment option with TAGRISSO® (osimertinib) (Sponsored)

from The Top Line · host Fierce Life Sciences

Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO® (osimertinib). AstraZeneca is focused on the development of new treatments, prioritizing researching options in eligible patients. Listen to the full podcast episode to learn more. Please see Important Safety Information for TAGRISSO. Please see complete Prescribing Information, including Patient Information for TAGRISSO.See omnystudio.com/listener for privacy information.

Episode metadata supplied by the publisher feed · Published Jan 10, 2025

Embed this episode

Attribution link and audio player

What this episode covers

Arun Krishna, VP and franchise head for an AstraZeneca US OBU, discusses a treatment option for patients.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

An additional treatment option with TAGRISSO® (osimertinib) (Sponsored)

0:00 14:25

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Top Line?

This episode is 14 minutes long.

When was this The Top Line episode published?

This episode was published on January 10, 2025.

Can I download this The Top Line episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!